Cardiovascular Disease

Nylidrin (hydrochloride) (Standard) is the analytical standard of Nylidrin hydrochloride (HY-B1404). This product is intended for research and analytical applications. Nylidrin hydrochloride (Buphenine hydrochloride) is an orally active β-adrenergic agonist. Nylidrin hydrochloride antagonizes NR1_A/2B NMDA receptors (IC₅₀ = 0.18 μM in Xenopus oocytes). Nylidrin hydrochloride reduces the levels of NP, HA, and M1. Nylidrin hydrochloride has antiviral activity against multiple H1N1 subtype influenza A viruses. Nylidrin hydrochloride improves hemorrhagic shock and anti-allergic effects.

RXFP1 receptor agonist-10 (Compound 188) is a RXFP1 receptor agonist (EC₅₀: 0.5 nM). RXFP1 receptor agonist-10 can be used for research of heart failure.

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat is an atrial natriuretic peptide (ANP) analog that relaxes smooth muscle without affecting cGMP levels.

Carazolol-d₆ (hydrochloride) is deuterium labeled Carazolol hydrochloride (HY-W517264). Carazolol hydrochloride is a highly potent antagonist of β₁/β₂ adrenoceptor. Carazolol hydrochloride is also a potent, selective β₃-adrenoceptor agonist. Carazolol hydrochloride can be used in the research of hypertension.

AS3288802, a highly selective active plasminogen activator inhibitor-1 (PAI-1) antibody, is a PAI-1 inhibitor with a human IC₅₀ and EC₅₀ values of 4.2 ng/mL. AS3288802 can be used for the research of thrombosis and fibrosis-related diseases.

Naxaprostene is a prostacyclin analogue. Naxaprostene was much more selective for IP receptors and tended towards partial agonism. Naxaprostene inhibits ADP-induced platelet aggregation. It has been shown to prevent rabbit carotid artery thrombosis.

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.

Aloracetam is a γ-aminobutyric acid cyclic derivative that can pass through the blood-brain barrier and has a significant enhancing cognitive function effect. Aloracetam improves the blood perfusion of brain tissue, increases the synthesis of proteins, ATP and acetylcholine in the brain, enhances the excitatory conduction effect of cholinergic nerves, and reduces the damage to brain tissue caused by cerebral vascular diseases. Aloracetam also has certain anti-epileptic, anti-inflammatory, analgesic and anti-depressant effects.

KT-362 is an intracellular calcium antagonist. KT-362 can inhibit NE-induced contractions and IP accumulation in vivo experiments.

P2Y1/P2Y6 antagonist 1 (Compound 3h) is an indolesulfonylhydrazide derivative. P2Y1/P2Y6 antagonist 1 is an orally active tP2Y1 and rP2Y6 antagonist (IC₅₀ of 9.72 and 1.89 μM, respectively). P2Y1/P2Y6 antagonist 1 can be used in the study of neurological diseases, inflammation, cardiovascular diseases and cancer.

Guaiol (Standard) is the analytical standard of Guaiol. This product is intended for research and analytical applications. Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC50 of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions[4]

TP-9201 is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. TP-9201 inhibits the interaction between GPIIb/IIIa and fibrinogen, thereby suppressing platelet aggregation. TP-9201 exhibits similar inhibitory activity on adenosine diphosphate (ADP) (HY-W010918)-induced platelet aggregation in humans, baboons, and dogs (IC₅₀ = 1-3 μM), while showing lower activity in rabbits (IC₅₀ = 45 μM) and rats (IC₅₀ = 20 μM). TP-9201can be used in studies related to the prevention of rethrombosis after arterial thrombolysis.

Benazepril-d₅ hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy.

SGC stimulator 2 is an orally active soluble guanylyl cyclase (sGC) stimulator with an EC₅₀ of 44 nM. SGC stimulator 2 exhibits inhibitory activity against the CB₂ receptor, with an IC₅₀ of 2.7 μM. SGC stimulator 2 activates native (Fe²⁺) sGC in a heme-dependent manner. SGC stimulator 2 produces sustained hypotensive effects in animal models. SGC stimulator 2 can be used for the research of hypertension.

PPACK is a potent, peptidic inhibitor targeting thrombin and granzyme GZMK. PPACK specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, PPACK exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. PPACK binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. PPACK is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases.

Fenofibrate-d₄ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Antioxidant agent-5 (compound D-6) is a potent antioxidant agent. Antioxidant agent-5 can inhibit oxLDL (oxidized low-density lipoprotein)-induced apoptosis and the expression of ICAM-1 and VCAM-1 in VECs. Antioxidant agent-5 suppresses oxLDL-induced increase of ROS level and nuclear translocation of NF-κB. Antioxidant agent-5 protects against oxLDL-induced endothelial injury by activating Nrf2/HO-1 anti-oxidation pathway.

SD3A is an antiplatelet agent. SD3A inhibits granule secretion and GP IIb/IIIa activation. SD3A inhibits mitochondrial function. SD3A has an antiaggregant effect on washed platelets stimulated with Collagen. SD3A results in reduced thrombus formation without affecting coagulation.

Scospondistatin is an anti-angiogenic peptide that can inhibit proliferation and migration of human umbilical vein endothelial cells in vitro.

Tyrosylhistidine is a dipeptide consisting of tyrosine and histidine (Tyr-His). Tyrosylhistidine is an orally active antihypertensive peptide. Tyrosylhistidine reduces blood pressure in mice in a model of spontaneous hypertension.